Can Acetaminophen Speed Soccer Recovery? One Small Trial

A single 1 g dose of acetaminophen before simulated soccer match-play helped male players regain neuromuscular function about 24 hours sooner than placebo in one small trial. The result is intriguing because the largest difference appeared in voluntary activation: the nervous system's ability to drive a muscle at maximum effort. It does not prove that acetaminophen is a general-purpose recovery supplement, and it says even less about using it repeatedly through a training block.

The study offers a plausible short-term option for an athlete facing a compressed competition schedule. It does not settle the larger question: whether regularly dampening pain-related signals could compromise the training adaptations that those hard sessions are meant to produce.

The trial: less loss of force, faster recovery

In a 2025 randomized, double-blind, placebo-controlled crossover trial by Bouchiba et al., 13 male soccer players completed simulated match-play after receiving either 1 g of acetaminophen or placebo. Because each player completed both conditions, each man acted as his own control. That design reduces noise from differences in baseline strength and fitness, though it cannot make a 13-person study precise.

The researchers tracked neuromuscular recovery for 72 hours. Maximal voluntary contraction, or MVC, fell 13.3% after acetaminophen and 24.7% after placebo. The reported between-condition difference was statistically significant. Players also performed better on 20-meter sprints across the recovery window with acetaminophen, and the study reported full neuromuscular recovery approximately 24 hours earlier than with placebo.

Those numbers describe performance and laboratory measures after one simulated match, not fewer injuries, better season-long availability, or a guaranteed advantage in a real fixture. The paper's available reporting does not provide confidence intervals for these effect estimates, so the range of plausible true effects remains unclear. Small crossover trials can find real effects, but they can also produce estimates that look larger than they would in a larger replication.

Why voluntary activation may be the more interesting result

MVC tells you how much force a player can voluntarily produce. It does not say whether the limitation comes mainly from the muscle or from the nervous system. The trial separated these components using voluntary activation, an electrophysiological measure of descending neural drive, and potentiated twitch force, a marker of peripheral contractile function.

The voluntary-activation deficit was 3.8% with acetaminophen versus 12.9% with placebo. In other words, the deficit in the placebo condition was about 3.4 times larger. Between-condition differences in peripheral twitch measures were smaller by comparison. That pattern is consistent with acetaminophen reducing pain-related sensory input that suppresses voluntary motor drive after hard exercise.

Consistent is not the same as proven. The study did not isolate a single pathway, so it cannot establish whether group III/IV muscle afferents, central analgesic actions, cyclooxygenase activity, or another process caused the difference. Creatine kinase and lactate dehydrogenase were measured, but the available results do not quantify between-condition effects for those muscle-damage markers. The trial therefore supports a central-fatigue interpretation more than it supports a claim that acetaminophen prevented muscle damage.

How unusual is this result in soccer recovery research?

Soccer recovery has no shortage of rituals, tubs, powders, and confident post-match advice. The evidence is less accommodating. A 2025 randomized trial of cold-water immersion, hot-water immersion, and placebo in national-level male soccer players found neither water-immersion strategy improved physical-performance recovery or training adaptations beyond placebo. That study assessed performance after a 90-minute simulated match and also followed repeated use across 15 weeks.

Its null result does not directly validate acetaminophen. The intervention, participants, duration, and endpoints differ. It does show why a positive recovery result should be judged against a field where popular practices often fail when tested against a credible placebo.

Other soccer-specific interventions have produced more favorable findings. In a 2024 randomized trial, daily 10-minute cold-water immersion during preseason improved muscle-damage biomarkers and neuromuscular recovery in 23 under-20 semiprofessional male players compared with rest. A double-blind curcumin crossover study in 15 collegiate soccer athletes reported better preservation of functional strength and lower muscle-damage markers after matches. These studies examine different protocols and outcomes, so they cannot rank acetaminophen against cold water or curcumin.

The wider supplement literature also resists tidy rankings. A 2025 systematic review and network meta-analysis evaluated dietary supplements for soccer performance, while a 2023 systematic review of elite soccer players concluded that support for many supplements was contradictory, scarce, or absent. Neither review establishes an acetaminophen recovery effect because neither provides an acetaminophen comparison relevant to this question.

The adaptation question remains unanswered

Acute competition recovery and repeated training recovery have different goals. Before a second match in three days, restoring sprint capacity and voluntary force may take priority. During a training block, some of the soreness, inflammation, and signaling after exercise may accompany the processes that produce adaptation.

Acetaminophen has cyclooxygenase-related activity, and prostaglandin signaling has been implicated in muscle repair and protein-synthesis pathways. Whether a standard acute 1 g dose meaningfully alters those processes in athletes is unresolved here. The available evidence contains no study of muscle protein synthesis, satellite-cell activity, hypertrophy, aerobic adaptation, or repeated acetaminophen dosing during training.

This is not evidence that one pre-match dose blunts gains. It is a reason not to convert a one-off competition finding into a daily recovery habit. The 15-week water-immersion trial is relevant as a reminder that recovery interventions can be tested against training adaptation; the acetaminophen trial did not include that test.

What the study can and cannot support

• Supported: In 13 male soccer players, a single pre-match 1 g acetaminophen dose was associated with smaller post-match declines in MVC and voluntary activation, better 20-meter sprint performance during 72 hours of recovery, and approximately 24 hours faster neuromuscular recovery than placebo.
• Reasonable inference: The disproportionate voluntary-activation result suggests that central fatigue, rather than peripheral contractile impairment alone, may account for much of the observed effect.
• Not established: Effects in women, other sports, real competitive matches, repeated dosing, longer training blocks, injury risk, or long-term performance.
• Not established: Whether acetaminophen meaningfully reduces peripheral muscle damage or changes training adaptation.

The trial also leaves practical uncertainties. The available report does not specify enough information to evaluate washout-related carryover risk in the crossover design. Its small sample cannot test whether responders differ by playing position, baseline fitness, injury history, or other characteristics. Female athletes were not studied, so hormonal-cycle effects on fatigue, recovery, and analgesic response remain outside the evidence.

A restrained practical verdict

For male soccer players with an immediate competition-recovery problem, this trial provides moderate-confidence evidence that one 1 g pre-match acetaminophen dose can improve recovery of neuromuscular capacity relative to placebo. The effect is potentially meaningful when the next match arrives quickly, but it rests on one small study and needs independent replication.

For routine training use, the answer is more conservative: do not assume the competition result applies. Frequent acetaminophen use adds unanswered questions about adaptation and athlete-specific safety, while the study provides no long-term liver-safety or drug-interaction data. Acetaminophen can cause serious liver injury when misused or combined with other acetaminophen-containing products, so athletes should follow labeled dosing and seek individualized medical advice when they have liver disease, use other medicines, or expect repeated use. One promising crossover trial is a reason to study the idea harder, not a license to treat the medicine cabinet as a recovery plan.